News | Computed Tomography (CT) | July 09, 2021

Reduced-dose CT depicts greater than 90% of lung nodules in children and young adults with cancer, identifying the presence of nodules with moderate sensitivity and high specificity

According to ARRS’ American Journal of Roentgenology (AJR), reduced-dose CT depicts greater than 90% of lung nodules in children and young adults with cancer, identifying the presence of nodules with moderate sensitivity and high specificity.

Axial reformatted clinical (1.083 mSv) and reduced dose (0.318 mSv) CT images from a 17-year-old girl with osteosarcoma. A 2 mm left lower lobe nodule is clearly visible in the left lower lobe on the clinical CT image (arrow in A). The same nodule is vaguely apparent on the reduced-dose CT image (arrow in B), classified as present but poorly visible.


July 9, 2021—According to ARRS’ American Journal of Roentgenology (AJR), reduced-dose CT depicts greater than 90% of lung nodules in children and young adults with cancer, identifying the presence of nodules with moderate sensitivity and high specificity.

“CT performed at 0.3 mSv mean effective dose has acceptable diagnostic performance for lung nodule detection in children and young adults and has the potential to reduce patient dose or expand CT utilization (e.g., to replace radiography in screening or monitoring protocols),” wrote corresponding author Andrew T. Trout of Cincinnati Children's Hospital Medical Center in Ohio.

Trout and colleagues’ prospective study enrolled patients 4–21 years old with known or suspected malignancy who were undergoing clinically indicated chest CT. Study participants underwent an additional investigational reduced-dose chest CT in the same imaging encounter. Three independent radiologists blind-reviewed the separated and deidentified CT examinations, with one radiologist performing a subsequent review to match nodules between the standard- and reduced-dose examinations.

Among the 78 patients (44 male, 34 female; mean age, 15.2 years) with cancer who underwent standard-dose chest CT and reduced-dose chest CT (mean effective dose 0.3 ± 0.1 mSv, representing 83% dose reduction) in the same imaging encounter, the reduced-dose protocol detected greater than 90% of lung nodules identified on the standard-dose examination.

Noting that no prior study has directly compared clinical to reduced-dose CT for detection of lung nodules in children, “reduced-dose CT may be a feasible option for detection of pulmonary metastatic disease in situations in which radiation dose is a primary consideration or as an option to reduce dose in patients undergoing serial chest CT to monitor known disease,” the authors of this AJR article concluded.

For more information: www.arrs.org


Related Content

News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
Subscribe Now